Skip to main content
. Author manuscript; available in PMC: 2025 Jun 1.
Published in final edited form as: Nat Med. 2024 Sep 14;30(12):3737–3747. doi: 10.1038/s41591-024-03267-1

Figure 4. Treatment blocks in which pCRs occurred in the HER2−Immune+ subtype.

Figure 4.

Of the 47 HER2−Immune+ patients receiving Dato-DXd + durvalumab in Block A, 20 proceeded directly to surgery, forgoing subsequent treatment; all of these patients had pathology-confirmed pCR (RCB 0). 54% of all cases achieving pCR in this subtype did so after the course of the Dato-DXd + durvalumab combination alone. Of the 27 patients receiving to Block B’s paclitaxel-based treatment, 14 of 19 who proceeded to surgery following treatment had pathology-confirmed pCR; 92% of all pCRs recorded in this subtype were achieved without the use of AC chemotherapy. Of the remaining 8 patients who received AC chemotherapy in Block C, 3 additional pCRs were recorded.